NASDAQ$TRVN
Trevena Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Trevena reported results for the third quarter of 2022, including a net loss of $15.3 million and a cash balance of $40.4 million. OLINVYK commercialization progressed with Vizient contract and receipt of CMS outpatient pass-through reimbursement. Positive Phase 1 topline results were reported for TRV045.
Trevena reported a net loss of $15.3 million for Q3 2022. The company's cash balance was $40.4 million as of September 30, 2022, expected to fund operations into Q3 2023. OLINVYK commercialization progressed and positive Phase 1 data was reported for TRV045.
- OLINVYK received CMS pass-through reimbursement for ambulatory surgical centers and hospital outpatient settings.
- Relationship with Vizient is advancing, enabling efficient resource management.
- Positive topline Phase 1 data was reported for TRV045, a novel S1P receptor modulator.
- Targeted TRV045 proof-of-concept study to assess CNS activity is planned for early 2023.
Headline financials
Revenue & EPS history
Trevena · Revenue · Quarterly
-$438K
Revenue by segment
Trevena · $69K total across 1 segment · Q4 2020
- Product Revenue$69K—100.0%
Forward guidance
Trevena expects its cash balance of $40.4 million as of September 30, 2022, will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the third quarter of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-2.3%
Avg return
Earnings day
-1.7%
Avg return
5 days after
-10.7%
Avg return
30 days after
44%
20 / 45 earnings
Positive
+15.1%
Q2 2020
Best reaction
-43.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2024 | +9.3% | +12.2% | -5.1% | |
| Q2 2024 | -16.0% | +6.2% | +32.5% | |
| Q1 2024 | -19.4% | -9.3% | -16.5% | |
| Q4 2023 | -19.4% | -9.3% | -16.5% | |
| Q4 2025 | +0.0% | -9.3% | -16.5% | |
| Q3 2023 | -1.5% | -3.2% | +1.0% | |
| Q2 2023 | +3.1% | +3.4% | -20.9% | |
| Q1 2023 | +2.9% | +14.1% | -7.4% | |
| Q4 2022 | -4.1% | +0.4% | -11.2% | |
| Q3 2022 | -43.9% | -33.0% | -50.0% | |
| Q2 2022 | +6.3% | +5.0% | -12.9% | |
| Q4 2021 | +13.8% | +4.1% | -32.7% | |
| Q1 2022 | +13.8% | +4.1% | -32.7% | |
| Q3 2021 | -17.1% | -21.2% | -25.9% | |
| Q2 2021 | -8.6% | -15.0% | -10.7% | |
| Q1 2021 | +2.8% | +3.9% | -5.0% | |
| Q4 2020 | -5.9% | +5.4% | -12.2% | |
| Q3 2020 | -6.5% | -8.8% | -8.4% | |
| Q2 2020 | +15.1% | -2.1% | -26.9% | |
| Q1 2020 | +4.0% | +21.0% | +45.4% | |
| Q4 2019 | -5.7% | -14.4% | -41.4% | |
| Q3 2019 | -20.4% | -23.9% | -32.1% | |
| Q2 2019 | +3.3% | +0.5% | -1.1% | |
| Q1 2019 | -9.0% | -13.5% | -32.3% | |
| Q4 2018 | -0.7% | +13.6% | +3.4% | |
| Q3 2018 | +7.2% | +10.0% | +2.6% | |
| Q2 2018 | +10.1% | +8.8% | +21.6% | |
| Q1 2018 | +8.2% | -3.4% | -13.0% | |
| Q4 2017 | +2.0% | -5.0% | -19.3% | |
| Q3 2017 | -2.7% | +18.7% | -4.7% | |
| Q2 2017 | -2.8% | -2.0% | -4.0% | |
| Q1 2017 | -4.1% | -6.2% | -24.8% | |
| Q4 2016 | -8.3% | -3.5% | -17.0% | |
| Q3 2016 | -8.3% | -8.8% | +19.1% | |
| Q2 2016 | +0.1% | +2.5% | -0.1% | |
| Q1 2016 | +3.3% | — | — | |
| Q4 2015 | -13.9% | — | — | |
| Q3 2015 | +1.5% | — | — | |
| Q2 2015 | +6.7% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +8.5% | — | — | |
| Q3 2014 | -0.9% | — | — | |
| Q2 2014 | +0.5% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | -7.0% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro